The whole debacle with Aducanumab combined with decades of failed amyloid-targeted treatments makes me a little bit skeptical of the drug. I'm definitely biased because of personal connections I...
The whole debacle with Aducanumab combined with decades of failed amyloid-targeted treatments makes me a little bit skeptical of the drug. I'm definitely biased because of personal connections I have with some prominent researchers in the anti-amyloid hypothesis camp, but it seems likely to me that amyloid plaques are a byproduct rather than a cause of the pathological process.
If Lecanemab shows real clinical efficacy, by all means, we should get it out to people, but I don't think it's going to be the last word in how dementia will be treated.
*WASHINGTON (AP) — Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early...
*WASHINGTON (AP) — Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the brain-robbing disease.
The drug, Leqembi, received conditional approval from the Food and Drug Administration in January based on early results suggesting it could slow Alzheimer’s progression by several months. The FDA now is reviewing more definitive results to decide whether the drug should receive the agency’s full endorsement.*
According to the article, the FDA's panel backing carries extra significance due to insurers holding off on paying for the infused treatment until fully backed by the FDA. Due to this, patients have had to pay approximately $26,500 per year for the drug, Leqembi(lecanemab-irmb).
The whole debacle with Aducanumab combined with decades of failed amyloid-targeted treatments makes me a little bit skeptical of the drug. I'm definitely biased because of personal connections I have with some prominent researchers in the anti-amyloid hypothesis camp, but it seems likely to me that amyloid plaques are a byproduct rather than a cause of the pathological process.
If Lecanemab shows real clinical efficacy, by all means, we should get it out to people, but I don't think it's going to be the last word in how dementia will be treated.
*WASHINGTON (AP) — Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the brain-robbing disease.
The drug, Leqembi, received conditional approval from the Food and Drug Administration in January based on early results suggesting it could slow Alzheimer’s progression by several months. The FDA now is reviewing more definitive results to decide whether the drug should receive the agency’s full endorsement.*
According to the article, the FDA's panel backing carries extra significance due to insurers holding off on paying for the infused treatment until fully backed by the FDA. Due to this, patients have had to pay approximately $26,500 per year for the drug, Leqembi(lecanemab-irmb).